Non-platinum based combination with trabectedine- PLD is an
option in patients with TFIp > 6 when platinum is not an option
•
Study OV-301 showed the superiority of trabectedine-PLD in
comparison to single agent PLD in terms of PFS for platinum- sensitive
patients
1
.
–
Exploratory analysis of patients with PFI-6-12 months treated with
platinum at progression showed superior OS
2
.
–
BRCA 1 mutated patients showed longer PFS and OS with
trabectedine-PLD
3
.
•
In which patients with TFIp > 6 months platinum is not an option?:
–
Residual toxicity (neuropathy)
–
Allergy to platinum
–
TFIp 6-12 months, especially beyond first relapse
1. Monk et al. J Clin Oncol 2010
2. Colombo et al. In J Gynecol Cancer 2011
3. Monk et al- Gynecol Oncol 2014
